USC Stem Cell scientists develop a game-changing organoid model to study human cerebellar development and disease
2024-01-04
(Press-News.org)
In a first for USC Stem Cell scientists, the laboratory of Giorgia Quadrato, an assistant professor of stem cell biology and regenerative medicine, has pioneered a novel human brain organoid model that generates all the major cell types of the cerebellum, a hindbrain region predominantly made up of two cell types necessary for movement, cognition, and emotion: granule cells and Purkinje neurons. This marks the first time that scientists have succeeded in growing Purkinje cells that possess the molecular and electrophysiological features of functional neurons in an all-human system. These breakthroughs in organoid-directed brain modeling have been published recently in the journal Cell Stem Cell.
“The reproducible co-development and maturation of the main cell types of the developing cerebellum in a human organoid model provide a new way to explore the underlying biology of cerebellar development and disorders and advance therapeutic interventions,” explained Quadrato, an assistant professor in the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at the Keck School of Medicine of USC.
The cerebellum controls movement and plays important roles in cognitive functions, including language, spatial processing, working memory, executive functions, and emotional processing.
Degeneration of Purkinje cells is associated with various neurodevelopmental and neurodegenerative disorders, including autism spectrum disorder and cerebellar ataxia, a condition that affects muscle movement.
Other neurons within the organoids—both excitatory neurons that share information, and inhibitory neurons that inhibit the sharing of information—formed circuits and showed coordinated network activity, demonstrating that they were also functional nerve cells. In addition, organoids formed human-specific progenitor cells, which are associated with medulloblastoma, the most prevalent metastatic brain tumor in children. This makes the organoids a potentially useful model for studying and finding treatments for this pediatric cancer.
Given the right external cues, the organoids could also be coaxed into forming anatomical features such as layers, mirroring normal embryonic brain development.
The organoid model creates a platform for discovering new treatments for variety of diseases.
“This study provides a physiologically relevant, all-human model system to elucidate the cell type-specific mechanisms governing cerebellar development and disease,” said Alexander Atamian, a PhD candidate in the Quadrato Lab and first author of the Cell Stem Cell study.
Additional co-authors are Macella Birtele, Negar Hosseini, Tuan Nguyen, Anoothi Seth, Ashley Del Dosso, and Marcelo P. Coba from USC; Sandeep Paul, Neil Tedeschi, and Ryan Taylor from Spatial Genomics; Ranmal Samarasinghe from UCLA; and Carlos Lois from the California Institute of Technology.
This project was funded by the Robert E. and May R. Wright Foundation, The Eli and Edythe Broad Foundation, and the Edward Mallinckdot, Jr. Foundation.
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-01-04
Researchers have uncovered evidence hinting that the most common bug spray ingredient, DEET, might cause reproductive problems by affecting the formation of egg cells during pregnancy.
The findings come from a study in C. elegans — worms that don’t look like they have much in common with humans yet serve as surprisingly useful bellwethers of how toxins in the environment affect human reproduction.
Get more HMS news here
The research, published Jan. 4 in iScience, raises difficult questions. Chief among them is how to balance the possible reproductive harms ...
2024-01-04
About The Study: The results of this study that included 573,000 persons suggest that hearing loss was associated with increased dementia risk, especially among people not using hearing aids, suggesting that hearing aids might prevent or delay the onset and progression of dementia. The risk estimates were lower than in previous studies, highlighting the need for more high-quality longitudinal studies.
Authors: Manuella Lech Cantuaria, Ph.D., of the University of Southern Denmark in Odense, is the corresponding author. (doi:10.1001/jamaoto.2023.3509)
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s ...
2024-01-04
About The Study: The findings of this study of 2,709 patients hospitalized with sepsis from 2016 to 2019 at an urban tertiary care center suggest a language-based inequity in outcomes. Further studies are needed to understand drivers of this inequity, how it may manifest in other diverse health systems, and to inform equitable care models for patients with limited English proficiency.
Authors: Neha P. Limaye, M.D., M.P.H., of Mount Sinai Hospital in New York, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link ...
2024-01-04
BOSTON – New research indicates that the eating disorder anorexia nervosa is associated with being an early riser, unlike many other disorders that tend to be evening-based such as depression, binge eating disorder and schizophrenia.
The study, which is published in JAMA Network Open and led by investigators at Massachusetts General Hospital (MGH), in collaboration with University College London and the University of the Republic in Uruguay, also revealed a link between anorexia nervosa and insomnia risk.
Previous research has suggested a possible connection between eating disorders and the body’s internal clock, or circadian clock, which controls a wide range of biological ...
2024-01-04
Press release: Princess Máxima Center for pediatric oncology
EMBARGO: JANUARY 4, 2024 AT 11:00 AM ET (US)
A detailed 'atlas' of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for pediatric oncology in the Netherlands mapped this childhood tumor at the level of individual cancer and immune cells. In doing so, they discovered a brake on the immune system that can be blocked with existing immunotherapy. The results in the lab are promising; preparations for a clinical study are underway.
Every year, 25 children in the Netherlands ...
2024-01-04
A new peer-reviewed study in the American Journal of Human Genetics highlights the work of the biobank at the Colorado Center for Personalized Medicine (CCPM), a world-class site for precision medicine in research and clinical care created in partnership with the University of Colorado Anschutz Medical Campus and UCHealth.
The paper focuses on CCPM’s research and personalized medical care.
“We’re one of the only institutions in the world that has accomplished the dual-purpose of using genetic information to accelerate scientific discovery in research while providing actionable clinical results to patients that ...
2024-01-04
In cooperation with research partners in Germany and France, the infectious disease specialist Dr Jan Rybniker and his team at University Hospital Cologne and the University of Cologne’s Faculty of Medicine have identified new, antibiotic molecules that target Mycobacterium tuberculosis and make it less pathogenic for humans. In addition, some of the discovered substances may allow for a renewed treatment of tuberculosis with available medications – including strains of the bacterium that have already developed drug resistance. The research has been published in the article ‘Discovery of dual-active ethionamide boosters ...
2024-01-04
At EPFL's School of Engineering, Professor Li Tang's Laboratory of Biomaterials for Immunoengineering has made significant strides in cancer treatment research. In laboratory settings, this innovative CAR-T therapy has consistently eradicated cancerous tumors in mouse models. Separately, in on-going clinical trials, eleven patients seemed to achieve complete remission using this treatment, marking a success rate of 100% to date. Notably, evidence from the lab study, published in Nature Biotechnology, suggests the therapy's long-term effectiveness, and indicates that its fabrication may be both quicker and more cost-effective ...
2024-01-04
MIAMI, FLORIDA (EMBARGOED UNTIL JAN. 4, 2024, at 10 AM EST) – Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes – and hope – to patients worldwide.
But treatment breakthroughs such as the immunotherapy drug teclistamab can lead to potentially lethal side effects, including cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).
These potential side effects have necessitated giving immunotherapy drugs in the hospital setting, where patients remain for five to seven days and receive other drugs ...
2024-01-04
A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection. They also found a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported.
The study appears Jan. 4, 2024, in the Journal of Medical Virology.
Paxlovid treatment for acute COVID-19 has been shown to be effective for high-risk unvaccinated individuals. But the effect of the treatment on long COVID risk, including whether it protects vaccinated people from getting long COVID, has been less clear.
The ...
LAST 30 PRESS RELEASES:
[Press-News.org] USC Stem Cell scientists develop a game-changing organoid model to study human cerebellar development and disease